Jean-Philippe Defour

List of Publications by Year
in descending order

28 papers	1,725 citations	516710 16 h-index	526287 27 g-index
29 all docs	29 docs citations	29 times ranked	2610 citing authors

#	Article	IF	Citations
1	What is the normal value of the neutrophil-to-lymphocyte ratio?. BMC Research Notes, 2017, 10, 12.	1.4	455
2	Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood, 2016, 127, 1325-1335.	1.4	261
3	Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood, 2016, 127, 333-342.	1.4	149
4	Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1241-1250.	7.1	98
5	Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia, 2015, 29, 249-252.	7.2	88
6	Orientation-specific signalling by thrombopoietin receptor dimers. EMBO Journal, 2011, 30, 4398-4413.	7.8	83
7	Tryptophan at the transmembraneâ€“cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2540-2545.	7.1	75
8	Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. Blood, 2019, 133, 2669-2681.	1.4	74
9	Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms. Leukemia, 2016, 30, 1214-1216.	7.2	56
10	The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin. Frontiers in Endocrinology, 2017, 8, 59.	3.5	56
11	Combination treatment for myeloproliferative neoplasms using <scp>JAK</scp> and panâ€class I <scp>PI</scp>3K inhibitors. Journal of Cellular and Molecular Medicine, 2013, 17, 1397-1409.	3.6	50
12	Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood, 2012, 119, 4625-4635.	1.4	49
13	Short telomeres increase the risk of severe COVID-19. Aging, 2020, 12, 19911-19922.	3.1	45
14	Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. Leukemia, 2020, 34, 510-521.	7.2	36
15	Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy. Blood, 2018, 132, 4-4.	1.4	32
16	His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor. Journal of Biological Chemistry, 2016, 291, 2974-2987.	3.4	29
17	A biological profile for diagnosis and outcome of COVID-19 patients. Clinical Chemistry and Laboratory Medicine, 2020, 58, 2141-2150.	2.3	20
18	MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491. Blood, 2020, 135, 948-953.	1.4	16

#	Article	IF	Citations
19	How to choose the right real-time RT-PCR primer sets for the SARS-CoV-2 genome detection?. Journal of Virological Methods, 2021, 295, 114197.	2.1	16
20	The S505A thrombopoietin receptor mutation in childhood hereditary thrombocytosis and essential thrombocythemia is S505N: single letter amino acid code matters. Leukemia, 2019, 33, 563-564.	7.2	7
21	Twoâ€•site evaluation of a new workflow for the detection of malignant cells on the Sysmex XNâ€1000 body fluid analyzer. International Journal of Laboratory Hematology, 2020, 42, 544-551.	1.3	6
22	An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis. Leukemia, 2017, 31, 1838-1839.	7.2	5
23	Biological variation data and analytical specification goal estimates of the thrombin generation assay with and without thrombomodulin in healthy individuals. International Journal of Laboratory Hematology, 2021, 43, 450-457.	1.3	5
24	Crispr/Cas9 Engineered 61bp Deletion in the Calr Gene of Mice Leads to Development of Thrombocytosis. Blood, 2016, 128, 4274-4274.	1.4	5
25	Characterization of Candida spp. interference on the Sysmex <scp>XN</scp>â€1000 body fluid mode. International Journal of Laboratory Hematology, 2018, 40, e28-e32.	1.3	4
26	Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms. Blood, 2018, 132, 2695-2699.	1.4	4
27	Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies. Leukemia and Lymphoma, 2019, 60, 1043-1052.	1.3	1
28	Can the 72-hour rule based on â€œBlast/Abn Lymphâ€•flag on Sysmex XN-10 optimize the workflow in hematology laboratory?. Annales De Biologie Clinique, 2019, 77, 422-428.	0.1	0